Haematology Cancer Clinical Guidelines

Haematology Expert Advisory Group (EAG)
on behalf of Northern Cancer Alliance

Title:	Haematology Cancer Clinical Guidelines
Authors:	Haematology EAG
Circulation List:	Haematology EAG Members
Contact Details:	Mrs C McNeill, Senior Administrator, Cancer Alliance
Telephone:	01138252976

Version History:

Date:	10.04.18	**Version:**	V17 – section 2	**Review Date:**	November 2019

Document Control

Version	Date	Summary	Review Date
V17			

Date Agreed: Haematology EAG members agreed the Guidelines on:
Emailed to group on 12.04.18, for formal endorsement at the next meeting.

Review Date: November 2019

CONTENTS

SECTION 1 NEHODS- Northern England Haemato- Diagnostic Service

SECTION 2 Guidelines for Cytogenetic analysis in Haematological Malignancies

SECTION 3 North of England Cancer Network Guidelines and Indications for PETCT

SECTION 4 Guidelines for management of Acute Myeloid Leukaemia (AML)

SECTION 5 Guidelines for Management of Myelodysplastic Syndromes

SECTION 6 Guidelines for Management of Acute Lymphoblastic Leukaemia

SECTION 7 Guidelines for the Management of Chronic Myeloid Leukaemia

SECTION 8
Guidelines for Management of Myeloproliferative Disorders
Polycythaemia Vera (PRV)
Myelofibrosis (MF)

SECTION 9
Guidelines for Management of Chronic Lymphocytic Leukaemia (CLL) and Lymphoproliferative Disorders
Hairy Cell Leukaemia
T-Prolymphocytic Leukaemia
Waldenstrom Macroglobulinaemia

SECTION 10
Guidelines for the Management of Low-grade Non-Hodgkin Lymphoma
Mantle Cell Lymphoma

SECTION 11 Guidelines for the Management of High Grade B Cell Non-Hodgkin Lymphoma (NHL)

SECTION 12 Guidelines for the Management of Classical Hodgkin Lymphoma

SECTION 13 Guidelines for the Management of Mature T-Cell and NK-Cell Neoplasms

SECTION 14 Guidelines for Management of Plasma Cell Myeloma

SECTION 15 Indications for Haemopoietic Stem Cell Transplantation

SECTION 16 Clinical Guideline for the prophylaxis and treatment of tumour lysis syndrome in patients receiving treatment for haematological malignancies

SECTION 17 Blood Transfusion Guidelines

SECTION Appendix
Appendix 1 – Teenage and Young Adult Pathway for initial Management
Appendix 2 – Pathway for follow up on completion of First line treatment
Appendix 3- TYA Designated Hospitals
Appendix 4 – NHS Specialised Services Pathway
Appendix 5 – Local Referral Pathways and Levels of Care
Appendix 6 - Pathways
Appendix 7 – Inter-provider transfers

- Multiple Myeloma
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma

SECTION 2

GUIDELINES FOR CYTOGENETIC ANALYSIS IN HAEMATOLOGICAL MALIGNANCIES

Genetic analysis of haematological malignancies

The following is the single **Cytogenetics / Molecular Genetics Laboratory** for the Haematology Expert Advisory Group of the Northern Cancer Alliance:

Northern Genetics Service,
Cytogenetics Laboratory,
Institute of Genetic Medicine,
Central Parkway,
Newcastle upon Tyne,
NE1 3BZ.

telephone: 0191 241 8703

email: cancer.cytogenetics@nuth.nhs.uk

Key Personnel:

Mr Gavin Cuthbert, FRCPath, Head of Cancer Cytogenetics

Dr Nick Bown, FRCPath, Head of Cytogenetics Laboratory.

Core service:

Chromosome analysis, FISH, MLPA, sequencing and RT-PCR to identify translocations / gene fusions and chromosome copy number abnormalities in haematological malignancies, including

AML:	PML-RARA [t(15;17)], PLZF-RARA [t(11;17)], RUNX1-RUNX1T1 [t(8;21)], CBFB-MYH11 [inv(16)], MECOM [3q27], MLL [11q23]. FLT3-ITD and NPM1 mutation analysis.
ALL:	ETV6-RUNX1 [t(12;21)], PAX5-ETV6 [t(9;12)], TCF3-PBX1 [t(1;19)], MLL-AF4 [t(4;11)], CALM-AF10 [t(10;11)], SIL-TAL1 [del(1p)], TCR A/B/G/D
CML:	BCR-ABL1 [t(9;22)]
MPN:	FIP1L1-PDGFRA [del(4q)], PDGFRB, FGFR1, CSF3R mutation analysis
Lymphoma:	IGH-CCND1 [t(11;14)], IGH-MYC [t(8;14)], IGH-BCL2 [t(14;18)], IGK [2p11], IGL [22q11], BCL6 [3q27], ALK [2p23], MALT1 [18q21] , BCL10 [1p22], MYD88 mutation analysis
Myeloma:	FGFR3-IGH [t(4;14)], IGH-MAF [t(14;16)], 1q gain, TP53 deletion

MDS: karyotype complexity, 5q and 7q loss

CLL: deletions of TP53, 11q,13q and trisomy12.

Notes

Bone marrow and Blood samples for Genetic study should be sent to the NEHODS specimen reception using a NEHODS Diagnostic Kit. These are distributed from NEHODS Centralised Specimen Reception.

NEHODS Specimen Reception
Flow Laboratory, Blood Sciences
Level 3 Leazes Wing
Royal Victoria Infirmary
Richardson Road
Newcastle upon Tyne
NE1 4LP
NEHODS Office tel: 0191 282 5028
email: tnu-tr.nehods@nhs.net

To maximise the chance of a successful result, samples should ideally be transported to Cytogenetics on the same day that they are taken.

Advance telephone or email warning of samples – particularly from high priority cases – is extremely helpful. The laboratory is open between 08.30 and 17.00. Special arrangements can be made for receipt and analysis of urgent samples outside these hours.

To manage workload and optimise reporting times, we may contact referring Haematologists by email to confirm the need for analysis and assess priority for individual samples.

Available on request – further details of test repertoire.

Please contact us to discuss requirements for new test development.

The laboratory is CPA accredited – no. 2212

****

Monitoring of allo-BMT by DNA microsatellite analysis (Molecular Genetics Laboratory, Northern Genetics Service)

Contact Tony Jackson tel. 0191 241 8775

Dr David Bourn, FRCPath.

email: molecular.genetics@nuth.nhs.uk

Molecular Diagnostics - Newgene

The following specific assays are provided by Newgene:
BCR-ABL quantitation
CML mutation screening
JAK2,MPL and CALR mutation screening
BRAF Mutation testing

Further details can be found on the website: www.newgene.org.uk

Contact:

NewGene Ltd., BioscienceBuilding
International Centre for Life
Newcastle upon Tyne
NE1 4EP

Tel: 0191 242 1923

Key personnel: Dr Ann Curtis, Scientific Director

email: info@newgene.org.uk
website: www.newgene.org.uk

JAK2/MPL/CALRSamples for Newgene should be sent to:-

Department of Haematology
Royal Victoria Infirmary
Queen Victoria Road
Newcastle upon Tyne
NE1 4LP

CML follow-up samples (transcript monitoring and kinase mutation screening) should be sent to:-
NewGene
Institute of Genetic Medicine,
Central Parkway,
Newcastle upon Tyne,
NE1 3BZ.

NB. samples for Diagnostic BCR/ABL1 testing and all other Haem-Onc Genetics studies – send to NEHODS Specimen Reception